Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-08-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to find out if a certain type of hormone therapy, gonadotropin-releasing hormone agonist (GnRH agonist), affects the way the body produces and responds to insulin. The investigators will evaluate the changes in insulin sensitivity during and after GnRH agonist treatment for prostate cancer. The investigators are assessing the possibility that treatment-related insulin resistance may contribute to the risk of diabetes and/or cardiovascular disease in men with prostate cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer

NCT00455624

Prostate Cancer

COMPLETED

Insulin Resistance Following ADT for Prostate CA

NCT04658849

Insulin Resistance Prostate Cancer

WITHDRAWN EARLY_PHASE1

Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

NCT01433913

Adenocarcinoma of the Prostate Recurrent Prostate Cancer Stage I Prostate Cancer +2 more

COMPLETED PHASE2

Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy

NCT03516110

Prostate Cancer

COMPLETED

Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer Treatment

NCT06217770

Prostate Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The study will be divided into 2 groups: one group (Cohort A) will consist of men undergoing GnRH agonist therapy for at least 24 months. The second group (Cohort B) will consist of men undergoing the same treatment but who are scheduled to receive only 6 months of treatment.
* The following tests and procedures will be performed when the participant joins the study, then at 3, 6, 12 and 24 months thereafter. (All visits will take place at the General Clinical Research Center (GCRC) at the Massachusetts General Hospital.) Height and weight; blood and urine samples; Oral Glucose Tolerance Test (OGTT), Dual energy X-ray Absorptiometry scan; medical history; and physical examinations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

GnRH agonist for 24 months

Gonadotropin Releasing Hormone Agonist Therapy

Intervention Type DRUG

Given either for 24 months and 6 months

Group 2

GnRH agonist for 6 months

Gonadotropin Releasing Hormone Agonist Therapy

Intervention Type DRUG

Given either for 24 months and 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gonadotropin Releasing Hormone Agonist Therapy

Given either for 24 months and 6 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adenocarcinoma of the prostate, clinical stage M0
* Scheduled to initiate GnRH agonist therapy with intended treatment duration of greater than 24 months (Group A)
* Scheduled for radiation therapy and neoadjuvant GnRH agonist therapy with intended 6 month duration of treatment (Group B)
* Karnofsky Performance Status 90 or 100
* Local or local-regional disease (Group B)

Exclusion Criteria

* Prior hormone therapy (GnRH agonist or antiandrogen)
* History of bilateral orchiectomy
* Known diabetes mellitus or glucose intolerance
* Current treatment with anabolic agents or metabolic agents known to affect insulin or glucose levels

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No